Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet
Condition: Celiac Disease Interventions: Drug: Placebo; Drug: TAK-101; Dietary Supplement: Gluten Sponsor: Takeda Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials